MétaCan
Menu
Back to cohort

Radium-223 in an international early access program (EAP): Effects of concomitant medication on overall survival in metastatic castration-resistant prostate cancer (mCRCP) patients.

2015· article· en· W2599238962 on OpenAlexaffabout
Fred Saad, Joan Carles, Silke Gillessen, Daniel Heinrich, Jeremy Gratt, Kurt Miller, Sten Nilsson, Joe M. O’Sullivan, Marcello Tucci, Manfred P. Wirth, Axel Heidenreich

Bibliographic record

VenueJournal of Clinical Oncology · 2015
Typearticle
Languageen
FieldMedicine
TopicProstate Cancer Treatment and Research
Canadian institutionsUniversité de Montréal
Fundersnot available
KeywordsMedicineConcomitantProstate cancerEnzalutamideInternal medicineDocetaxelAsymptomaticBone painUrologyCancerSurgeryGastroenterology

Abstract

fetched live from OpenAlex

5034 Background: The pivotal ALSYMPCA study reported improved overall survival (OS) in bone symptomatic mCRPC patients (pts) treated with radium-223 (Ra-223) vs placebo (median 14.9 vs 11.6 months [mos], HR = 0.70). Data from 696 EAP pts recruited from 14 countries (Europe, Canada, Israel) are presented. Methods: In this prospective phase IIIb study, mCRPC pts with symptomatic or asymptomatic bone metastases (no visceral disease) received Ra-223, 50 kBq/kg (iv injection) every 4 weeks for 6 cycles. Primary endpoints were safety and OS. The effects of concomitant medications, baseline (BL) pain, alkaline phosphatase (ALP) and ECOG PS on OS were assessed. Results: 696 pts were treated; 58% received all 6 Ra-223 injections. At BL: median age was 72 years; 88% of pts were ECOG PS 0–1; pain was reported as: no pain, mild-moderate, and severe in 21%, 52%, and 27% respectively. 60% of pts received prior therapy with docetaxel. For pts treated with concomitant therapy: 22% were with abiraterone; 20% with denosumab; 18% with bisphosphonates and 4% with enzalutamide. Grade 3/4 AEs were reported in 38% of pts; 21% discontinued Ra-223 due to AEs. At the time of analysis median OS was 16 mos [13–not estimated (NE)]. Median time to first SSE was 18 mos [17–NE]; 24% of pts had ≥ 50% confirmed ALP decrease from BL; 8% had > 50% confirmed PSA decrease from BL. In post hoc analyses OS was statistically significantly longer in pts with BL: ALP <220 U/L vs ≥ 220 U/L; ECOG PS 0–1 vs ≥ 2; no pain vs mild-moderate vs severe; concomitant denosumab; concomitant abiraterone (Table). Conclusions: In Ra-223 treated pts, OS appeared to be better in those treated concomitantly with denosumab or abiraterone. Significantly longer OS was observed in pts with a good ECOG PS, no pain and low ALP. Clinical trial information: 2012-000075-16. Characteristic Pts, n Median OS, mos (95% CI) Log-rank p-value Concomitant denosumab Yes 138 NA (15–NE) 0.00940 No 558 13 (12–NE) Concomitant abiraterone Yes 156 NA (16–NE) < 0.0001 No 540 14 (12–16) ALP < 220U/L 431 NA (NE) < 0.0001 ≥ 220U/L 263 10 (9–11) ECOG-PS 0-1 609 17 (14–NE) < 0.0001 ≥ 2 87 7 (5–11) Pain No 146 NA (16–NE) 0.00018* Mild-moderate 360 15 (13–NE) Severe 163 11 (8–12) *No vs all pain. NA, not available.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.001
Threshold uncertainty score0.005

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.195
GPT teacher head0.542
Teacher spread0.347 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations20
Published2015
Admission routes2
Has abstractyes

Explore more

Same venueJournal of Clinical OncologySame topicProstate Cancer Treatment and ResearchFrench-language works237,207